N. Vaissière

发表

GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer

W. Engel-Riedel, R. Fietkau, R. Huber, 2016, Strahlentherapie und Onkologie.

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

H. Schuitemaker, D. Heerwegh, J. Sadoff, 2022, Vaccine.

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting

Mathieu Le Gars, H. Schuitemaker, D. Heerwegh, 2021, medRxiv.

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

R. Ramlau, M. Krzakowski, J. Jassem, 2014, Clinical lung cancer.

Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.

J. Douillard, S. Hiret, J. Bennouna, 2011, Lung cancer.

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

S. Culine, J. Bellmunt, W. Su, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

R. Ramlau, M. Krzakowski, A. Santoro, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

M. Espié, V. Ganju, P. Conte, 2013, Anticancer research.

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

M. Espié, P. Conte, P. Conte, 2009, British Journal of Cancer.

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

M. Riggi, M. Reck, P. Cornes, 2009, Lung cancer.

All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.

M. Espié, P. Conte, N. Tubiana-Mathieu, 2009 .

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

V. Ganju, P. Conte, N. Tubiana-Mathieu, 2010 .

3612 Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit

S. Barni, R. James, O. Hansen, 2009 .

Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit

S. Barni, R. James, O. Hansen, 2010 .